Roth Capital analyst Elemer Piros upgrades Unity Biotechnology (NASDAQ:UBX) from Neutral to Buy and maintains $4 price target.
89bio’s Pegozafermin Data Shows Improved Liver Fat, Glycemic Control
89bio Inc (NASDAQ:ETNB) announced the presentation of data from the ENTRIGUE Phase 2 proof-of-concept trial of pegozafermin in severe hypertriglyceridemia (SHTG)…